- Home
- INZY vs FRGE Comparison
INZY vs FRGE Comparison
Compare INZY & FRGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- FRGE
- Stock Information
- Founded
- INZY 2015
- FRGE 2014
- Country
- INZY United States
- FRGE United States
- Employees
- INZY N/A
- FRGE N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- FRGE Computer Software: Prepackaged Software
- Sector
- INZY Health Care
- FRGE Technology
- Exchange
- INZY Nasdaq
- FRGE Nasdaq
- Market Cap
- INZY 188.2M
- FRGE 176.0M
- IPO Year
- INZY 2020
- FRGE N/A
- Fundamental
- Price
- INZY $1.72
- FRGE $0.71
- Analyst Decision
- INZY Strong Buy
- FRGE Buy
- Analyst Count
- INZY 8
- FRGE 4
- Target Price
- INZY $17.75
- FRGE $4.50
- AVG Volume (30 Days)
- INZY 666.9K
- FRGE 707.2K
- Earning Date
- INZY 11-05-2024
- FRGE 11-06-2024
- Dividend Yield
- INZY N/A
- FRGE N/A
- EPS Growth
- INZY N/A
- FRGE N/A
- EPS
- INZY N/A
- FRGE N/A
- Revenue
- INZY N/A
- FRGE $79,799,000.00
- Revenue This Year
- INZY N/A
- FRGE $19.18
- Revenue Next Year
- INZY N/A
- FRGE $35.98
- P/E Ratio
- INZY N/A
- FRGE N/A
- Revenue Growth
- INZY N/A
- FRGE 18.08
- 52 Week Low
- INZY $1.62
- FRGE $0.70
- 52 Week High
- INZY $7.80
- FRGE $3.56
- Technical
- Relative Strength Index (RSI)
- INZY 23.86
- FRGE 29.94
- Support Level
- INZY $2.68
- FRGE $0.70
- Resistance Level
- INZY $3.18
- FRGE $0.99
- Average True Range (ATR)
- INZY 0.28
- FRGE 0.08
- MACD
- INZY -0.08
- FRGE -0.02
- Stochastic Oscillator
- INZY 6.71
- FRGE 3.45
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About FRGE Forge Global Holdings Inc.
Forge Global Holdings Inc is a financial service platform created to serve the needs of the private market. It provides marketplace infrastructure, data services, and technology solutions for private market participants. The Company offers a trusted trading platform, proprietary data and insights to inform investment strategies, along with custody services to help companies, shareholders, institutions and accredited investors confidently navigate and transact in the private market.